Merck goes in deeper with Keytruda/Lynparza combo; PureTech unveils stem cell therapy startup
→ Merck is opening up a new wing of its Keytruda pipeline, devoting it to a slate of new Phase III combination studies with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
